The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance GSK reported core earnings of $1.09 per American depositary share (ADS) for second-quarter 2024, beating the Zacks Consensus Estimate of $1.00.

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price target of p1,500.00. The company’s shares closed yesterday ...

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares opened today ...

Expect Glaxo To Increase Consumer Focus As Walmsley Takes Driving Seat Sep. 22, 2016 8:57 AM ET GSK plc (GSK) Stock NVS, BAYRY, SNY MRK GSK 2 Comments EP Vantage 4.17K Follower s ...

This is what I learned. GSK Focused On Minimizing Need For Cumulative Drug Exposure Glaxo is the second-largest HIV company, with revenue of about $5.2 billion versus Gilead's $12.9 billion.

GSK also recorded sales of £1 million from its share of contracted European volumes of COVID-19 booster vaccine, co-developed in partnership with Sanofi. Sales rose 34%, excluding COVID-19 solutions.